Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belimumab-Based Plasma Cell Targeted Therapy to Impact Transplant Eligibility

NCT02500251 is registered in ClinicalTrials.gov with E. Steve Woodle as lead sponsor.

NCT NCT02500251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belimumab-Based Plasma Cell Targeted Therapy to Impact Transplant Eligibility
Lead sponsor
E. Steve Woodle
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2015
Completion date
August 31, 2018
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplant rejection